|
#226
29.09.2009, 18:31
|
||||
|
||||
|
Îáçîð ïî îáìåíó æåëåçà íàãëÿäíî ïëþñ åãî êîððåêöèÿ ïðè ëå÷åíèè ÕÑÍ è ÕÏÍ â ñâîáîäíîì äîñòóïå:
Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14 Suppl 1:22-33. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] 
|
|
#227
01.10.2009, 06:46
|
||||
|
||||
|
Èçáèðàòåëüíûå èíãèáèòîðû çàõâàòà ñåðîòîíèíà ó áåðåìåííûõ ìîãóò âûçûâàòü ÂÏÑ ïëîäà
Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study; Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH; British Medical Journal (BMJ) 339 b3569 (2009)
OBJECTIVE: To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations. DESIGN: Population based cohort study. PARTICIPANTS: 493 113 children born in Denmark, 1996-2003. MAIN OUTCOME MEASURE: Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005. RESULTS: Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low-for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI. CONCLUSION: There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI.
|
|
#228
01.10.2009, 06:48
|
||||
|
||||
|
Åùå ðàç ïðî ïàíòîïðàçîë ó ïàöèåíòîâ, ïîëó÷àþùèõ êëîïèäîãðåëü
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study; Frere C, Cuisset T, Quilici J, Poyet R, Gaborit B, Bali L, Brissy O, Morange PE, Alessi MC, Bonnet JL; Journal of the American College of Cardiology (JACC) 54 (13), 1149-53 (Sep 2009)
OBJECTIVES: This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS). BACKGROUND: Use of omeprazole has been reported to significantly decrease the clopidogrel antiplatelet effect because of cytochrome P450 interaction. Because all PPIs are metabolized by CYP2C19, but to a varying degree, we hypothesized that the reported negative omeprazole-clopidogrel drug interaction may not be caused by a class effect. METHODS: A total of 104 patients undergoing coronary stenting for NSTE ACS were prospectively included and randomized to omeprazole or pantoprazole 20 mg. They received at discharge 75-mg aspirin and 150-mg clopidogrel. Platelet reactivity index (PRI) vasoactive stimulated phosphoprotein (VASP) was used to assess clopidogrel response and adenosine diphosphate (ADP)-induced aggregation for platelet reactivity (ADP-Ag). RESULTS: After 1 month, patients receiving pantoprazole had a significantly better platelet response to clopidogrel as assessed with the PRI VASP: 36 +/- 20% versus 48 +/- 17% (p = 0.007). We identified more clopidogrel nonresponders in the omeprazole group than in the pantoprazole group: 44% versus 23% (p = 0.04), odds ratio: 2.6 (95% confidence interval: 1.2 to 6.2). Conversely, we did not observe any significant difference in platelet reactivity with ADP-Ag between the omeprazole and pantoprazole groups: 52 +/- 15% and 50 +/- 18%, respectively (p = 0.29). CONCLUSIONS: The present findings suggest the preferential use of pantoprazole compared with omeprazole in patients receiving clopidogrel to avoid any potential negative interaction with CYP2C19.
|
|
#230
03.10.2009, 13:09
|
||||
|
||||
|
10 points to remember about the ACCF/AHA 2009 performance measures for primary prevention of CVD (J Am Coll Cardiol).
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Treatment with a selective endothelin-receptor antagonist to reduce BP. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Just Launched: Use Cardiosource's new On-Label Resource Centers to get current information on appropriate use of certain therapeutics, including Multaq. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] TCT 2009: Get complete coverage of TCT, including videos and presentation slides. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] New for your patients: What you need to know about blood thinners. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] New Expert Opinion: Drs. Bernhard Bischoff and Joerg Hausleiter on Radiation Dose in Cardiac CT. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Prospective Validation of the Prognostic Usefulness of Brain Natriuretic Peptide in Asymptomatic Patients With Chronic Severe Mitral Regurgitation Pizarro R, Bazzino OO, Oberti PF, et al. J Am Coll Cardiol 2009;54:1099-1106. Study Question: What is the independent and additive prognostic value of brain natriuretic peptide (BNP) in patients with severe asymptomatic mitral regurgitation and normal left ventricular function? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Fluvastatin and Perioperative Events in Patients Undergoing Vascular Surgery Schouten O, Boersma E, Hoeks SE, et al. N Engl J Med 2009;361:980-989. Study Question: Does perioperative statin therapy improve postoperative incidence of adverse cardiac events in patients undergoing vascular surgery? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation Singer DE, Chang Y, Fang MC, et al. Ann Intern Med 2009;151:297-305. Study Question: What is the net clinical benefit (considering thromboembolic and hemorrhagic risk) of warfarin therapy in patients with atrial fibrillation (AF)? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Improved Oral Anticoagulation After a Dietary Vitamin K-Guided Strategy: A Randomized Controlled Trial de Assis MC, Rabelo ER, Ávila CW, Polanczyk CA, Rohde LE. Circulation 2009;120:1115-1122. Study Question: Will a strategy of modifying dietary vitamin K intake improve management of oral warfarin therapy compared with a conventional dosage adjustment strategy? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Effects of Initiating Insulin and Metformin on Glycemic Control and Inflammatory Biomarkers Among Patients With Type 2 Diabetes: The LANCET Randomized Trial Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM. JAMA 2009;302:1186-1194. Study Question: What is the effect of insulin alone or combined with metformin in lowering levels of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and soluble tumor necrosis factor receptor 2 (sTNFr2) in patients with recent-onset type 2 diabetes mellitus? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Effects of Donor Pretreatment With Dopamine on Graft Function After Kidney Transplantation: A Randomized Controlled Trial Schnuelle P, Gottmann U, Hoeger S, et al. JAMA 2009;302:1067-1075. Study Question: What is the effect of pretreatment of brain-dead donors with low-dose dopamine on early graft function in human renal transplant recipients? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney Disease Receiving Antihypertensive Therapy Weinberg JM, Appel LJ, Bakris G, et al., on behalf of the African American Study of Hypertension and Kidney Disease Collaborative Research Group. Arch Intern Med 2009;169:1587-1594. Study Question: What is the incidence and what are the factors associated with hyperkalemia in patients with chronic kidney disease (CKD) treated with angiotensin-converting enzyme inhibitors (ACEIs) and other antihypertensive drugs? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#231
08.10.2009, 09:12
|
|||
|
|||
|
Äåôèáðèëëÿòð ïîñëå ÈÌ íå íóæåí (IRIS)
Defibrillator Implantation Early after Myocardial Infarction Gerhard Steinbeck at al. NEJM [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Background The rate of death, including sudden cardiac death, is highest early after a myocardial infarction. Yet current guidelines do not recommend the use of an implantable cardioverter–defibrillator (ICD) within 40 days after a myocardial infarction for the prevention of sudden cardiac death. We tested the hypothesis that patients at increased risk who are treated early with an ICD will live longer than those who receive optimal medical therapy alone. Methods This randomized, prospective, open-label, investigator-initiated, multicenter trial registered 62,944 unselected patients with myocardial infarction. Of this total, 898 patients were enrolled 5 to 31 days after the event if they met certain clinical criteria: a reduced left ventricular ejection fraction ([Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]40%) and a heart rate of 90 or more beats per minute on the first available electrocardiogram (ECG) (criterion 1: 602 patients), nonsustained ventricular tachycardia ([Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]150 beats per minute) during Holter monitoring (criterion 2: 208 patients), or both criteria (88 patients). Of the 898 patients, 445 were randomly assigned to treatment with an ICD and 453 to medical therapy alone. Results During a mean follow-up of 37 months, 233 patients died: 116 patients in the ICD group and 117 patients in the control group. Overall mortality was not reduced in the ICD group (hazard ratio, 1.04; 95% confidence interval [CI], 0.81 to 1.35; P=0.78). There were fewer sudden cardiac deaths in the ICD group than in the control group (27 vs. 60; hazard ratio, 0.55; 95% CI, 0.31 to 1.00; P=0.049), but the number of nonsudden cardiac deaths was higher (68 vs. 39; hazard ratio, 1.92; 95% CI, 1.29 to 2.84; P=0.001). Hazard ratios were similar among the three groups of patients categorized according to the enrollment criteria they met (criterion 1, criterion 2, or both). Conclusions Prophylactic ICD therapy did not reduce overall mortality among patients with acute myocardial infarction and clinical features that placed them at increased risk. (ClinicalTrials.gov number, NCT00157768 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] .)
|
|
#232
09.10.2009, 20:39
|
||||
|
||||
|
GDF-15 Predicts M&M After CRT
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Statin therapy and risk of developing type 2 DM (Diabetes Care). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Prognostic value of stress myocardial perfusion and late gadolinium enhancement imaging by CMR (Circulation). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Immediate Risk-Stratification Improves Survival (IRIS). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#234
10.10.2009, 08:50
|
|||
|
|||
|
Öèòàòà:
Âîïðîñ ïðèìåðíî èç ñåðèè: "À Âû âåñü æóðíàë Circulation, ïðî÷èòûâàåòå îò êîðêè äî êîðêè?". Êàæäûé ÷èòàåò, ÷òî åìó èíòåðåñíî.
|
|
#235
10.10.2009, 12:58
|
||||
|
||||
|
Öèòàòà:
1. Íîâèçíû èíôîðìàöèè 2. Ñïåöèàëüíîñòè è èíòåðåñîâ þçåðà 3. Óìåíüøåãíèÿ òðàòû íà ïîèñê è äîñòóï ê èíôîðìàöèè. 4. Âîçìîæíîñòè ïðîñìîòðà âèäåî è ïðîñëóøèâàíèÿ ãîëîñîâîé èíôîðìàöèè. 5. ×àñòî ññûëêó ìîæíî íå àêòèâèðîâàòü, äîñòàòî÷íî èíôîðìàöèè â çàãîëîâêå. 6. Ñàìî ñóùåñòâîâàíèå áèáëèîòåêè êîíãðåññà ÑØÀ íå ãàðàíòèðóåò, ÷òî êàæäûé âîøåäøèé òóäà ïðî÷èòàåò âñå êíèãè è ïðîñìîòðèò âñå ôèëüìû.
|
|
#236
16.10.2009, 20:16
|
||||
|
||||
|
Is a Pre-Operative Brain Natriuretic Peptide or N-Terminal Pro–B-Type Natriuretic Peptide Measurement an Independent Predictor of Adverse Cardiovascular Outcomes Within 30 Days of Noncardiac Surgery? A Systematic Review and Meta-Analysis of Observational Studies
Karthikeyan G, Moncur RA, Levine O, et al. J Am Coll Cardiol 2009;1599-1606. Study Question: Is preoperative brain natriuretic peptide (BNP) an independent predictor of adverse cardiovascular events after noncardiac surgery? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Systematic Strategy of Prophylactic Coronary Angiography Improves Long-Term Outcome After Major Vascular Surgery in Medium- to High-Risk Patients: A Prospective, Randomized Study Monaco M, Stassano P, Di Tommaso L, et al. J Am Coll Cardiol 2009;54:989-996. Study Question: What is the impact of a strategy of routine coronary angiography on immediate- and long-term outcome of patients at medium to high risk who are scheduled to undergo vascular surgery? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Incidence and Predictors of Silent Myocardial Infarction in Type 2 Diabetes and the Effect of Fenofibrate: An Analysis From the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Burgess DC, Hunt D, LiPing L, et al. Eur Heart J 2009;Sep 29:[Epub ahead of print]. Study Question: What is the effect of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the FIELD study? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Aetiology of Sudden Cardiac Death in Athletes in the United Kingdom: A Pathological Study de Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN. Heart 2009;95:1409-1414. Study Question: What are the demographics and etiology of sudden cardiac death (SCD) in athletes referred to a tertiary cardiac pathology center in the United Kingdom? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Immediate vs Delayed Intervention for Acute Coronary Syndromes: A Randomized Clinical Trial Montalescot G, Cayla G, Collet JP, et al., on behalf of the ABOARD Investigators. JAMA 2009;302:947-954. Study Question: Is immediate intervention on admission better than delayed intervention in patients with non–ST-elevation acute coronary syndrome (NSTEMI-ACS)? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Dual Antiplatelet Therapy for More Than 12 Months After Percutaneous Coronary Intervention: Insights From the Guthrie PCI Registry Harjai KJ, Shenoy C, Orshaw P, Boura J. Heart 2009;95:1579-1586. Study Question: Is there a benefit of continuing dual antiplatelet (DAP) therapy for longer than 1 year after a percutaneous coronary intervention (PCI)? Dual Antiplatelet Therapy for More Than 12 Months After [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Obesity and Cardiovascular Thrombotic Events in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents Wang ZJ, Zhou YJ, Liu YY, et al. Heart 2009;95;1587-1592. Study Question: What is the effect of obesity on cardiovascular thrombotic events after stent implantation? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Multislice Computed Tomography Coronary Angiography for Risk Stratification in Patients With an Intermediate Pretest Likelihood van Werkhoven JM, Gaemperli O, Schuijf JD, et al. Heart 2009;95:1607-1611. Study Question: Is multislice CT coronary angiography useful for risk stratification of patients suspected of coronary artery disease (CAD)? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Relationship Between Baseline Coronary Calcium Score and Demonstration of Coronary Artery Stenoses During Follow-Up: MESA (Multi-Ethnic Study of Atherosclerosis) Rosen BD, Fernandes V, McClelland RL, et al. JACC Cardiovasc Imaging 2009;2:1175-1183. Study Question: Does coronary artery calcium score predict extent of coronary stenosis? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Independent Value of Left Atrial Volume Index for the Prediction of Mortality in Patients With Suspected Heart Failure Referred From the Community Lim TK, Dwivedi G, Hayat S, Majumdar S, Senior R. Heart 2009;95:1172-1178. Study Question: Is there independent power of left atrial volume index (LAVI) to predict mortality in patients with suspected heart failure (HF) referred from the community? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] A Randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients With Type 2 Diabetes: The Sleep AHEAD Study Foster GD, Borradaile KE, Sanders MH, et al., on behalf of the Sleep AHEAD Research Group of the Look AHEAD Research Group. Arch Intern Med 2009;169:1619-1626. Study Question: What is the effect of weight loss on obstructive sleep apnea (OSA) over a 1-year period in diabetics? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Outcomes following endovascular vs. open repair of AAA (OVER). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#237
17.10.2009, 00:14
|
|||
|
|||
|
Ìîæåò êîìó ïðèãîäèòñÿ
 .Interpreting Difficult ECGs: A Rapid Reference. By Springhouse, Lippincott Williams & Wilkins Publication Date: 2005-11-01. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#238
17.10.2009, 00:17
|
|||
|
|||
|
 ïðîäîëæåíèå:
Cardiac Catheterization and Coronary Intervention. Oxford Specialist Handbooks in Cardiology. Publisher:Oxford University Press, USA. 2008-06-02 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#239
17.10.2009, 01:08
|
|||
|
|||
|
Îäíà èç ëó÷øèõ êíèã ïî äèô.äèàãíîñòèêå, òî÷íåå 5 êíèã â îäíîé. Ðåêîìåíäóþ âñåì, ó êîãî åùå íåò.
Ferri's Clinical Advisor 2009: 5 Books in 1 Publisher: Mosby | Pages: 1680 | 2008-07-07 | ISBN 0323041345 |CHM | 57.5 MB [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#240
20.10.2009, 20:17
|
||||
|
||||
|
Priniciples for Comparative Effectiveness Research
Date: 2009 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
Ëèíåéíûé âèä
